Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) of the Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts. Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Pithampur Facility. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ('Listing Regulations') Piramal Pharma Ltd - 543635 - Board Meeting Intimation for Regulation 29 And Regulation 50 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 ,inter alia, to consider and approve Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March, 2023 Piramal Pharma Ltd - 543635 - Compliance Certificate Pursuant To Regulation 40(10) And 61(4) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Compliance Certificate pursuant to Regulation 40(10) and 61(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') Piramal Pharma Ltd - 543635 - Compliance Certificate Pursuant To Regulation 40(10) And 61(4) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Pursuant to Regulation 40(10) and 61(4) of the Listing Regulations, enclosed please find the Compliance Certificate issued by Mr. Ainesh Jethwa, Practicing Company Secretary for the financial year ended 31st March, 2023. Piramal Pharma Ltd - 543635 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyPiramal Pharma Ltd 2CIN NO.U24297MH2020PLC338592 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1153.79 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Tanya Sanish Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Vivek Valsaraj Designation: Chief Financial Officer EmailId: [email protected] Date: 25/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Piramal Pharma Ltd - 543635 - Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') For The Financial Year Ended 31St March, 2023
Compliance Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') for the financial year ended 31st March, 2023 Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Successful Closure Of US FDA Inspection At Piramal Pharma'S Manufacturing Facility Located At Sellersville, USA
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Sellersville, USA Piramal Pharma Ltd - 543635 - Intimation Under Regulations 30 And 51 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Credit Rating
Intimation under Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Credit Rating